RE:RE:RE:RE:Yet more on the meeting with managementThis is no doubt why Soleus was so taken by TH-1902 very early on. Better efficacy and longer treatment time. It is a powerful combination as long as there are no other offsetting factors that have either not arisen yet or havhe not been revelaed yet. The AACR could be very interesting for us as that is most likely when we will hear things of this nature.
scarlet1967 wrote: “10 cycles”! That is quite a statement. So overall good tolerability. Would they aim for such prolonged treatment for late stage cancers if they had serious/even less serious adverse effects so far? What else can this possibly mean, good on target/off target delivery ratio (better affinity to the sortilin)? Higher intracellular concentration of the docetaxel (by passing the efflux and less free floating docetaxel in the plasma)? Higher potential efficacy due to higher intracellular concentration of docetaxel for longer period of time? Interpret it the way you want to me it is quite an ambitious goal, a sign of confidence so far based on the data they have collected.